Literature DB >> 34152061

Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34152061      PMCID： PMC8262302          DOI： 10.1002/onco.13865

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  1 in total

1.  A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer.

Authors:  Pin Zhang; Binghe Xu; Lin Gui; Wenna Wang; Meng Xiu; Xiao Zhang; Guilan Sun; Xiaoyu Zhu; Jianjun Zou
Journal:  Biomark Res       Date:  2021-04-12
  1 in total
  1 in total

1.  Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.

Authors:  Qiancheng Hu; Wenli Kang; Qingfeng Wang; Ting Luo
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.